We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

131 hedge funds and large institutions have $254M invested in Catalyst Pharmaceutical in 2020 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 49 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

243% more call options, than puts

Call options by funds: $819K | Put options by funds: $239K

11% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 19

8% more capital invested

Capital invested by funds: $236M → $254M (+$18.3M)

2.78% more ownership

Funds ownership: 60.98% → 63.76% (+2.8%)

1% more funds holding

Funds holding: 130 → 131 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 49

Holders
131
Holders Change
+1
Holders Change %
+0.77%
% of All Funds
2.89%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
21
Increased
44
Reduced
49
Closed
19
Calls
$819K
Puts
$239K
Net Calls
+$580K
Net Calls Change
+$850K

Top Buyers

1
MP
Mangrove Partners
Connecticut
+$11.5M
2
PVI
Pura Vida Investments
New York
+$5.94M
3
OM
Opaleye Management
Massachusetts
+$4.31M
4
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
+$4M
5
Millennium Management
Millennium Management
New York
+$3.29M

Top Sellers

1
N
Nuveen
North Carolina
-$7.18M
2
Squarepoint
Squarepoint
New York
-$3.11M
3
Prudential Financial
Prudential Financial
New Jersey
-$3.04M
4
Two Sigma Investments
Two Sigma Investments
New York
-$2.87M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$2.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$32.6M +$84.5K +20,585 +0.2%
State Street
2
State Street
Massachusetts
$28.6M +$92.5K +22,527 +0.3%
AC
3
Armistice Capital
New York
$20.8M +$1.23M +300,000 +6%
Vanguard Group
4
Vanguard Group
Pennsylvania
$19.8M +$1.39M +337,702 +7%
MP
5
Mangrove Partners
Connecticut
$16.8M +$11.5M +2,807,100 +181%
Morgan Stanley
6
Morgan Stanley
New York
$10.4M -$619K -150,696 -5%
Goldman Sachs
7
Goldman Sachs
New York
$7.56M +$154K +37,469 +2%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$5.93M +$152K +37,036 +2%
PVI
9
Pura Vida Investments
New York
$5.57M +$5.94M +1,446,953 New
Schroder Investment Management Group
10
Schroder Investment Management Group
United Kingdom
$5.21M +$4M +974,809 +276%
Northern Trust
11
Northern Trust
Illinois
$4.74M -$20.4K -4,958 -0.4%
AQR Capital Management
12
AQR Capital Management
Connecticut
$4.67M +$317K +77,305 +7%
Marshall Wace
13
Marshall Wace
United Kingdom
$4.26M -$1.9M -462,138 -29%
BBA
14
Baker Bros. Advisors
New York
$4.08M -$1.15M -281,188 -21%
OM
15
Opaleye Management
Massachusetts
$4.04M +$4.31M +1,050,000 New
Prudential Financial
16
Prudential Financial
New Jersey
$3.96M -$3.04M -741,815 -42%
Citadel Advisors
17
Citadel Advisors
Florida
$3.37M -$1.3M -317,449 -27%
Charles Schwab
18
Charles Schwab
California
$3.33M +$226K +55,039 +7%
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$3.33M +$1M +244,416 +39%
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$3.21M +$945K +230,162 +38%
Millennium Management
21
Millennium Management
New York
$3.21M +$3.29M +801,306 +2,528%
JP Morgan Chase
22
JP Morgan Chase
New York
$3.05M -$556K -135,488 -15%
Renaissance Technologies
23
Renaissance Technologies
New York
$2.85M +$2.31M +563,526 +321%
RA
24
Royce & Associates
New York
$2.48M -$561K -136,791 -18%
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$2.1M +$514K +125,342 +30%
1
2 3 4 5

CPRX Hedge Fund Activity: Q1 2020 in Review

131 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2020, worth a combined $254M — up 7.8% from $236M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new CPRX positions and 19 closed out — a net gain of 2 holders — while 44 added to existing stakes and 49 trimmed.

The largest buyer was Mangrove Partners, adding an estimated $11.5M. The largest seller was Nuveen, cutting an estimated $7.18M.

  • 131 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2020, up from 130 in Q4 2019.
  • Funds reported $254M of Catalyst Pharmaceutical stock for Q1 2020, up 7.8% quarter-over-quarter.
  • 21 funds opened new Catalyst Pharmaceutical positions in Q1 2020 and 19 closed out, a net change of +2 holders.
  • The largest Catalyst Pharmaceutical buyer in Q1 2020 was Mangrove Partners, an estimated $11.5M added.
  • The largest Catalyst Pharmaceutical seller in Q1 2020 was Nuveen, an estimated $7.18M sold.

Based on aggregated 13F filings for Q1 2020.